ANAB: AnaptysBio Inc Price to Sales
Risk minimization through the transfer of antibody rights to industry giants protects AnaptysBio, Inc. (ANAB) capital, which drives the price action. The current price-to-sales ratio demonstrates the impact of this strategy, where the 6.00 mark serves as the relevant indicator. Growth is fueled by Jemperli royalties to develop the immune pipeline, while revenues are based on partner payments and the treatment of skin pathologies.
Metric breakdowns and analytics for AnaptysBio Corp (ANAB)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ANAB - Net Profit|Expected Profit AnaptysBio, Inc.|ANAB - P/E Multiple|Market Cap to Projected Earnings AnaptysBio Inc|ANAB - Price/Earnings to Growth Ratio|Company Value to EBITDA AnaptysBio Corp|ANAB - Operating profit before deduction of amortization|Earnings per share for the trailing year AnaptysBio|ANAB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months anaptysbio.com|ANAB - Earnings per share growth in current year|Projected earnings per share growth rate for next year AnaptysBio, Inc.
- total revenue and sales volume data:
Summary company analytics:anaptysbio.com
The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for a business relative to its actual sales. Analyzing the ratio of market capitalization to revenue helps identify whether AnaptysBio, Inc. (ANAB) quotes are overheated, which is critical when optimizing R&D expenses through external contractors who eliminate production risks but impact the final capitalization efficiency.
Who AnaptysBio, Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|AUPH: Price-to-Sales Ratio|BioCryst - Market Cap to Revenue|Market Cap to Sales Volume VERA (veratx.com)|DNTH: Market Cap to Revenue|Price to Sales Pharvaris NV|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|TRML - Price-to-Revenue Coefficient|PGEN (Precigen, Inc.) - P/S Multiple|Price-to-Revenue Ratio PHAR|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Price to Sales|GOSS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|PVLA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Savara Corp|Market Cap to Revenue Ratio RIGL (Rigel Corp)|P/S Multiple ATXS|Market Cap to Revenue engene.com ENGN|RAPT Therapeutics - Market Cap to Revenue|Price-to-Revenue Coefficient Aerovate Therapeutics, Inc. (JBIO)|Aclaris - P/S Multiple|KYTX - P/S Multiple|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CABA|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|P/S Multiple Theratechnologies, Inc.|P/S Multiple AVTX|Price-to-Revenue Ratio ELDN (Eledon Pharmaceuticals, Inc)|Price-to-Revenue Ratio Agenus AGEN|CLYM (climbbio.com) - Price-to-Sales Ratio|Zura Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Labs Inc|EQ: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Market Cap to Revenue immunic-therapeutics.com IMUX|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|XFOR: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Enlivex Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple Q32 Bio Inc QTTB|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|P/S Multiple Bolt Bio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|P/S Multiple Aditxt Inc. ADTX|GRI - Price-to-Revenue Ratio|Price-to-Sales Ratio XRTX|HIND (ReShape Lifesciences) - Market Cap to Revenue|REVB: Market Cap to Sales Volume|Market Cap to Revenue INDP|Price to Sales scinai.com SCNI|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|Price-to-Revenue Coefficient affimed.com|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Market Cap to Revenue THRD
